| Date | Title | Description | Source |
| 20.05.2022 | Athersys tries to post-hoc-analyze its way out of anoth... | Athersys’ stem cell therapy has failed yet again.
In a 206-person trial conducted in Japan, ... | endpts.com... |
| 25.06.2021 | For now, stem cells for Covid-19 are mostly a shot in the da... | The uncertainty over how to effectively treat Covid-19 is proving to be an opportunity for people in... | statnews.c... |
| 17.01.2020 | Peter Ciriello takes over the reins at Vygon USA; Mirum P... | Peter Ciriello
→ Peter Ciriello has climbed to the upper echelons of the French medical de... | endpts.com... |
| 17.01.2019 | Despite market uncertainty, healthcare CEOs of all stripes r... | The market gyrations and the shutdown. The trade wars and global uncertainty.
None of the above has... | medcitynew... |
| 12.10.2018 | Meeting’s nearly fourfold attendance growth highlights cell,... | This was a far cry from the first meeting in 2006, when around 350 scientists huddled for warmth aga... | medcitynew... |
| 28.04.2014 | First efficacy trial of Athersys stem cell therapy yields di... | Cleveland-based Athersys (NASDAQ: ATHX) released the interim results today for the Phase 2 study it’... | medcitynew... |
| 14.08.2013 | Stem cell firm Athersys faces enrollment struggles with one ... | Already the company has two Phase 2 trials in progress, although one has been held up by enrollment ... | medcitynew... |
| 13.03.2013 | Stem cell company Athersys expects more R&D spending, po... | Promoted
Covid-19’s terrible toll on diabetes patients. What can be done?
The public health crisis... | medcitynew... |
| 04.04.2012 | Athersys awarded stem cell patent for graft-versus-host dise... | The patent pertains to Athersys’ MultiStem technology, an off-the-shelf stem cell treatment derived ... | medcitynew... |
| 02.04.2012 | Athersys CEO: Stroke therapy could be one of biggest blockbu... | So were Van Bokkelen’s bold pronouncements a legitimate assessment of MultiStem’s outlook, or just e... | medcitynew... |
| 27.03.2012 | Athersys gets OK for German solid organ transplant clinical ... | Enrollment will begin in the second half of the year and Athersys will provide “modest and limited” ... | medcitynew... |
| 09.03.2012 | Stem cell company Athersys secures $9M in private stock sale | Athersys’ shares were trading down about 10 percent to $1.75 late Friday morning.
The company said ... | medcitynew... |
| 01.02.2012 | Stem cell company Athersys gets grant to study traumatic bra... | The grant will fund research that will include preclinical safety and efficacy studies required to s... | medcitynew... |
| 01.02.2012 | Athersys touts results of phase 1 blood diseases trial | Athersys made a similar announcement last May about the interim results of the trial.
The company’s... | medcitynew... |
| 04.01.2012 | Athersys gets U.S. stem cell patent for heart attack, other ... | “Cardiovascular disease represents an important opportunity area for MultiStem therapy, and [this] p... | medcitynew... |
| 16.11.2011 | Covidien beats The Street, confirms 2012 guidance | Earnings... | Covidien (NYSE:COV) beat Wall Street’s earnings expectations for both its fourth quarter and 2011 fi... | massdevice... |
| 14.11.2011 | Athersys closes $20 million stock purchase deal with Aspire ... | “We have historically obtained capital through a combination of business partnerships, grant funding... | medcitynew... |
| 10.08.2011 | Athersys prepares for stroke, heart attack phase 2 clinical ... | Stem cell therapy developer Athersys (NASDAQ:ATHX) plans to begin phase 2 clinical trials of its Mul... | medcitynew... |
| 28.01.2011 | Athersys to raise $13M in direct offering; shares tumble | “Shareholder dilution is just kind of a reality for an early stage biotech,” said Lauren Migliore, a... | medcitynew... |
| 28.01.2011 | Athersys looks to raise $13.1 million in private offering | Stem cell company Athersys Inc. (NSDQ:ATHX) has reached an agreement to sell about $13 million of it... | massdevice... |
| 03.01.2011 | Ex-Cleveland Clinic CEO Floyd Loop leaves Athersys board | Loop joined Athersys’ board in 2007, after retiring from Cleveland Clinic in 2004. When he started a... | medcitynew... |
| 18.11.2010 | Analyst: Athersys poised for stroke market with MultiStem | The most promising application of Athersys Inc.’s (NSDQ:ATHX) stem cell technology lies in treating ... | massdevice... |
| 10.09.2010 | Athersys loses VC board member | A member of stem cell company Athersys Inc.’s (NDSQ:ATHX) board of directors has resigned.
As of Se... | massdevice... |
| 24.05.2010 | Athersys stem cell therapy wins scientists’ plaudits | By Mary Vanac
Doctors and researchers at the Athersys Inc. (NSDQ:ATHX) investor meeting in New York... | massdevice... |
| 15.05.2010 | Experts laud potential of Athersys stem cell therapy MultiSt... | “We and a growing number of others believe that MultiStem represents a significant advance in the fi... | medcitynew... |
| 22.02.2010 | OrbiMed Advisors raises $550M for health venture fund | Last year, OrbiMed led a $25 million Series B round for Oakwood-based ViewRay, which is developing a... | medcitynew... |
| 16.02.2010 | Athersys finishes enrolling heart attack patients for stem c... | Athersys plans to use catheters to deliver its MultiStem therapy to the damaged regions of patient... | medcitynew... |
| 10.02.2010 | Athersys gets U.S., European patents for investigational ste... | Athersys said Wednesday it has been granted U.S. patent 7,659,118, which covers its non-embryonic, m... | medcitynew... |
| 14.01.2010 | Biopharmaceutical company Athersys seeks to register 20 mill... | If Athersys did sell shares or warrants — promises to sell shares at a certain price on a future dat... | medcitynew... |
| 04.01.2010 | University of Cincinnati students experiment with medical de... | A new and improved Hillcrest Hospital should be up and running by this time next year, thanks to aÂ... | medcitynew... |
| 23.12.2009 | Athersys therapy ‘good fit’ for Pfizer Regenerative Medicine... | On Monday, the Pfizer unit struck a development and commercialization agreement with Athersys Inc., ... | medcitynew... |
| 22.12.2009 | New tax on medical device manufacturers could force Invacare... | Nationwide Children’s Hospital in Columbus recently was awarded an initial $5.5 million contract f... | medcitynew... |
| 21.12.2009 | Athersys Inc. shares more than double on Pfizer agreement to... | “We think that having Pfizer as our partner is an important statement about the quality of the work ... | medcitynew... |
| 08.12.2009 | Cleveland Clinic gets grants, license agreement, invests in ... | Promoted
Telemedicine’s potential to provide healthcare to the world’s most vulnerable
Teladoc Hea... | medcitynew... |
| 02.12.2009 | MedCity News on WKYC-TV: The future of Cleveland biopharma’s... | Athersys said last month that it continued enrollments in safety and efficacy trials for MultiStem, ... | medcitynew... |
| 06.11.2009 | Athersys still looking for funders of stem cell study for st... | CLEVELAND, Ohio — Athersys Inc. continued enrollments during the third quarter in safety and effica... | medcitynew... |
| 13.08.2009 | Words to lead by: Retired Cleveland Clinic CEO Floyd Loop wr... | Dr. Loop retired from the Cleveland Clinic in October 2004 after leading the health care system for ... | medcitynew... |
| 10.03.2009 | Pappas Ventures closes $102 million life science fund | “We have long been intrigued by the medical research activity in places like Indiana and Ohio,” said... | medcitynew... |
| 12.06.2007 | Cleveland biotech Athersys raises $65M with reverse-merger | Athersys, a Cleveland, Ohio biotech, went public via reverse merger and raised $65 million in a priv... | venturebea... |
| - | Athersys CEO: Stroke therapy could be one of biggest blockbu... | Gil Van Bokkelen, CEO of stem cell company Athersys (NASDAQ:ATHX), is typically one to speak in caut... | medcitynew... |
| - | MedCity News on WKYC-TV: The future of Cleveland biopharma’s... | Mary Vanac, MedCity News’ vice president and Ohio bureau chief, joined syndication partner WKYC-TV T... | medcitynew... |
| - | Biopharmaceutical company Athersys seeks to register 20 mill... | CLEVELAND, Ohio — Biopharmaceutical company Athersys Inc. is seeking to register 20 million shares o... | medcitynew... |
| - | Stem cell company Athersys expects more R&D spending, po... | Cleveland-based Athersys (NYSE:ATHX) has a full plate as it continues to advance its “off the shelf”... | medcitynew... |
| - | Athersys closes $20 million stock purchase deal with Aspire ... | A new common stock purchase agreement with Aspire Capital Fund LLC will give Cleveland biopharmaceut... | medcitynew... |
| - | Cleveland Clinic gets grants, license agreement, invests in ... | The Cleveland Clinic has received a $2.75 million federal grant to study the use of stem cells in tr... | medcitynew... |
| - | Athersys gets U.S., European patents for investigational ste... | Updated 4:39 p.m.
CLEVELAND, Ohio — Biopharmaceutical company Athersys Inc. has received two patent... | medcitynew... |
| - | Athersys awarded stem cell patent for graft-versus-host dise... | Stem cell developer Athersys (NASDAQ:ATHX) has received a U.S patent that covers the use of nonembry... | medcitynew... |
| - | Ex-Cleveland Clinic CEO Floyd Loop leaves Athersys board | Floyd Loop, the former Cleveland Clinic CEO credited with turning around the once-struggling hospita... | medcitynew... |
| - | Pappas Ventures closes $102 million life science fund | North Carolina-based Pappas Ventures closed its fourth fund, a $102 million round that will invest i... | medcitynew... |
| - | New tax on medical device manufacturers could force Invacare... | News and notes from the day in MedCity, Ohio:
A new tax on medical device manufacturers in the U.S.... | medcitynew... |
| - | OrbiMed Advisors raises $550M for health venture fund | NEW YORK, New York — OrbiMed Advisors, which has invested in Ohio companies Athersys Inc. and ViewRa... | medcitynew... |
| - | Stem cell company Athersys gets grant to study traumatic bra... | Stem cell developer Athersys (NASDAQ:ATHX) has received $3.6 million in new grant funding, with one ... | medcitynew... |
| - | Meeting’s nearly fourfold attendance growth highlights cell,... | The Alliance for Regenerative Medicine’s (ARM’s) annual Cell and Gene Meeting needs a bigger boat. N... | medcitynew... |
| - | Athersys gets U.S. stem cell patent for heart attack, other ... | Athersys (NASDAQ:ATHX) has obtained a U.S. patent that covers the use of nonembryonic multi-potent s... | medcitynew... |
| - | Stem cell company Athersys secures $9M in private stock sale | Stem cell developer Athersys (NASDAQ:ATHX) has secured $9 million in a private placement with an uni... | medcitynew... |
| - | Athersys finishes enrolling heart attack patients for stem c... | CLEVELAND, Ohio –Â Biopharmaceutical company Athersys Inc. has finished enrolling patients for a Pha... | medcitynew... |
| - | Athersys to raise $13M in direct offering; shares tumble | Stem cell company Athersys Inc. (NASDAQ:ATHX) has reached an agreement to sell about $13 million of ... | medcitynew... |
| - | Stem cell firm Athersys faces enrollment struggles with one ... | Thanks in part to a SBIR Fast Track grant worth up to $2.8 million, stem cell company Athersys (Nasd... | medcitynew... |
| - | Athersys Inc. shares more than double on Pfizer agreement to... | Updated 5:00 p.m.
CLEVELAND, Ohio — Biopharmaceutical company Athersys Inc. is in line for up to $1... | medcitynew... |
| - | Despite market uncertainty, healthcare CEOs of all stripes r... | The market gyrations and the shutdown. The trade wars and global uncertainty.
None of the above has... | medcitynew... |
| - | Athersys gets OK for German solid organ transplant clinical ... | Stem cell developer Athersys (NASDAQ:ATHX) has received German regulatory clearance for a physician-... | medcitynew... |
| - | Athersys touts results of phase 1 blood diseases trial | Stem cell therapy developer Athersys (NASDAQ:ATHX) reported positive results from a phase 1 clinical... | medcitynew... |
| - | Athersys prepares for stroke, heart attack phase 2 clinical ... | Stem cell therapy developer Athersys (NASDAQ:ATHX) plans to begin phase 2 clinical trials of its Mul... | medcitynew... |
| - | Experts laud potential of Athersys stem cell therapy MultiSt... | Doctors and researchers at the Athersys Inc. (NASDAQ: ATHX) investor meeting in New York City expres... | medcitynew... |
| - | Words to lead by: Retired Cleveland Clinic CEO Floyd Loop wr... | Updated 3:57 p.m. Friday, Aug. 14, 2009
CLEVELAND, Ohio –Â Health care reform, rising costs, fallin... | medcitynew... |
| - | University of Cincinnati students experiment with medical de... | News and notes from the day in MedCity, Ohio:
Danielle Everman had never heard of pelvic prolapse u... | medcitynew... |
| - | Athersys therapy ‘good fit’ for Pfizer Regenerative Medicine... | CLEVELAND, Ohio — Ruth McKernan helped start Pfizer Regenerative Medicine — a research-oriented busi... | medcitynew... |
| - | First efficacy trial of Athersys stem cell therapy yields di... | Edited to include comments from CEO.
Halfway through its first large-scale efficacy trial, Athersys... | medcitynew... |
